MX2023002522A - Compuestos novedosos para usar en el tratamiento de enfermedades asociadas con la angiotensina ii. - Google Patents

Compuestos novedosos para usar en el tratamiento de enfermedades asociadas con la angiotensina ii.

Info

Publication number
MX2023002522A
MX2023002522A MX2023002522A MX2023002522A MX2023002522A MX 2023002522 A MX2023002522 A MX 2023002522A MX 2023002522 A MX2023002522 A MX 2023002522A MX 2023002522 A MX2023002522 A MX 2023002522A MX 2023002522 A MX2023002522 A MX 2023002522A
Authority
MX
Mexico
Prior art keywords
sup
treatment
angiotensin
novel compounds
diseases associated
Prior art date
Application number
MX2023002522A
Other languages
English (en)
Spanish (es)
Inventor
Tomas Fex
Bengt Ohlsson
Original Assignee
Vicore Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vicore Pharma Ab filed Critical Vicore Pharma Ab
Publication of MX2023002522A publication Critical patent/MX2023002522A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2023002522A 2020-09-01 2021-09-01 Compuestos novedosos para usar en el tratamiento de enfermedades asociadas con la angiotensina ii. MX2023002522A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2013721.2A GB202013721D0 (en) 2020-09-01 2020-09-01 New compounds
PCT/GB2021/052254 WO2022049372A1 (en) 2020-09-01 2021-09-01 Novel compounds for use in the treatment of diseases associated with angiotensin ii

Publications (1)

Publication Number Publication Date
MX2023002522A true MX2023002522A (es) 2023-03-13

Family

ID=72749608

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002522A MX2023002522A (es) 2020-09-01 2021-09-01 Compuestos novedosos para usar en el tratamiento de enfermedades asociadas con la angiotensina ii.

Country Status (13)

Country Link
US (1) US20230348444A1 (cg-RX-API-DMAC7.html)
EP (1) EP4208460A1 (cg-RX-API-DMAC7.html)
JP (2) JP2023539614A (cg-RX-API-DMAC7.html)
KR (1) KR20230058467A (cg-RX-API-DMAC7.html)
CN (1) CN116568682B (cg-RX-API-DMAC7.html)
AU (1) AU2021337193A1 (cg-RX-API-DMAC7.html)
CA (1) CA3189240A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023000580A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023002347A2 (cg-RX-API-DMAC7.html)
GB (1) GB202013721D0 (cg-RX-API-DMAC7.html)
IL (1) IL300582A (cg-RX-API-DMAC7.html)
MX (1) MX2023002522A (cg-RX-API-DMAC7.html)
WO (1) WO2022049372A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202104038D0 (en) * 2021-03-23 2021-05-05 Vicore Pharma Ab New compounds
JP2024511453A (ja) * 2021-03-23 2024-03-13 ヴィコール ファルマ アーベー 選択的アンジオテンシンii受容体リガンド
GB202104033D0 (en) * 2021-03-23 2021-05-05 Vicore Pharma Ab New compounds
WO2023193733A1 (zh) * 2022-04-06 2023-10-12 武汉人福创新药物研发中心有限公司 一种at2r激动剂
CN120569378A (zh) * 2023-01-09 2025-08-29 维科尔药物公司 选择性血管紧张素ii化合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198438A (en) * 1991-05-07 1993-03-30 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
US5312820A (en) 1992-07-17 1994-05-17 Merck & Co., Inc. Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines
US5444067A (en) 1993-08-30 1995-08-22 Merck & Co., Inc. Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety
SE9800550D0 (sv) 1998-02-24 1998-02-24 A & Science Invest Ab A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
YU78601A (sh) * 1999-05-05 2005-07-19 Aventis Pharma Deutschland Gmbh. 1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže
JP4707321B2 (ja) * 2001-05-31 2011-06-22 ヴィコール・ファルマ・アーベー アンギオテンシンiiアゴニストとして有用な三環式化合物
DE60222409T2 (de) 2001-05-31 2008-09-25 Vicore Pharma Ab Trizyklische verbindungen, nützlich als angiotensin ii agonisten
AU2003302106A1 (en) 2002-11-21 2004-06-15 Vicore Pharma Ab New tricyclic angiotensin ii agonists
AU2006235698B2 (en) * 2005-04-12 2012-03-29 Vicore Pharma Ab New tricyclic angiotensin II agonists
US8835471B2 (en) 2010-06-11 2014-09-16 Vicore Pharma Ab Use of angiotensin II agonists
US20170266164A1 (en) 2014-12-12 2017-09-21 Vicore Pharma Ab New methods and uses
WO2016107879A2 (en) 2014-12-30 2016-07-07 Vicore Pharma Ab New use of angiotensin ii receptor agonists
HK1244232A1 (zh) 2015-03-02 2018-08-03 维科尔药物公司 用於治疗肺纤维化的血管紧张素ii受体激动剂
WO2017221012A1 (en) 2016-06-21 2017-12-28 Vicore Pharma Ab Methods and compositions for preventing or reducing the risk of cancer treatment-related cardiotoxicity
GB201710906D0 (en) 2017-07-06 2017-08-23 Vicore Pharma Ab Compounds and methods for treating peripheral neuropathy
GB201913603D0 (en) * 2019-09-20 2019-11-06 Vicore Pharma Ab New compounds

Also Published As

Publication number Publication date
CA3189240A1 (en) 2022-03-10
GB202013721D0 (en) 2020-10-14
JP2023539614A (ja) 2023-09-15
EP4208460A1 (en) 2023-07-12
CN116568682B (zh) 2026-07-24
US20230348444A1 (en) 2023-11-02
AU2021337193A1 (en) 2023-03-23
CO2023002347A2 (es) 2023-05-19
JP2026126247A (ja) 2026-08-04
WO2022049372A1 (en) 2022-03-10
KR20230058467A (ko) 2023-05-03
CL2023000580A1 (es) 2023-10-06
IL300582A (en) 2023-04-01
CN116568682A (zh) 2023-08-08

Similar Documents

Publication Publication Date Title
MX2024000518A (es) Nuevos compuestos selectivos de angiotensina ii.
PH12022550564A1 (en) New compounds
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
ZA202403923B (en) Heterocyclic compounds as immunomodulators
MX2020011501A (es) Compuestos novedosos.
MX2020013570A (es) Compuestos de purinona y su uso en el tratamiento del cancer.
PH12022552056A1 (en) Heterocyclic glp-1 agonists
EP4699609A3 (en) Heterocyclic glp-1 agonists
GEP20267860B (en) Condensed tryciclic pyrroles as alpha-1 antitrypsin modulators
MX2020010369A (es) Particulas implantables y metodos relacionados.
JOP20190151A1 (ar) مركبات أمينو - ترايازولو بيريدين واستخدامها في علاج سرطان
CO2023002347A2 (es) Compuestos novedosos para usar en el tratamiento de enfermedades asociadas con la angiotensina ii
MX389965B (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos
EP4603094A3 (en) New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild)
CR20240312A (es) Macrociclos de imidazol para el tratamiento de enfermedades autoinmunitarias
EA200601747A1 (ru) Три(цикло)замещённые амидные соединения
MY206327A (en) Formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
MX2021012223A (es) Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria.
WO2023102162A8 (en) Novel hdac inhibitors and therapeutic use thereof
MX2024014329A (es) Compuestos de azolo para el tratamiento de enfermedades fibroticas
MX2025000659A (es) Compuestos de imidazopiridina, preparacion de los mismos y usos terapeuticos de los mismos
MX2022002187A (es) Composicion de amida peptidica y metodo para su preparacion.
CR20220231A (es) Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria
Kalinin et al. Proline-based hydroxamates targeting the zinc-dependent deacetylase LpxC: synthesis, antibacterial properties, and docking studies